South32
Rio Tinto (ASX:RIO) Drops 6% on Glencore Merger Talks: Is This the Buying Opportunity or a Warning Sign?
Rio Tinto and Glencore's Merger Proposal Rio Tinto (ASX: RIO) fell over 6 per cent on Friday after Glencore confirmed the two mining giants are in early merger talks. The deal would combine Rio's A$200 billion market cap with Glencore's £53 billion to create a resources powerhouse worth roughly US$260 billion in enterprise value. Yet…
Investors
Australian Investors Assess Emerging Opportunities Across Global Markets
Australian investors are increasingly taking a strategic approach to portfolio construction as global markets evolve and traditional asset correlations shift. With equity valuations under scrutiny, interest rates remaining a key variable, and new financial instruments gaining traction, investors are reassessing where long-term value can be found. Understanding how emerging trends fit within an overall investment…
Monadelphous
Monadelphous (ASX:MND) Hits All-Time High on $535m BHP and Rio Tinto Contracts: Buy or Take Profits?
Monadelphous  Hits Record High on $535m Contracts Monadelphous (ASX: MND) surged to an all-time high of A$28.89 this week after announcing another A$110 million in new contracts, capping off an extraordinary run that has seen the engineering services company secure approximately A$535 million in work over recent weeks. The stock has more than doubled over…
Canyon Resources
Canyon Resources (ASX:CAY) Surges 7% as Cameroon Bauxite Mine Nears Production: Time to Buy?
Canyon Resources Targets Bauxite Production by 2026 Canyon Resources (ASX: CAY) is gaining strong momentum as the company approaches a major turning point in its journey from developer to producer. Canyon jumped 6.8% to A$0.24 on Thursday after releasing a development update confirming that mining at the flagship Minim Martap Bauxite Project in Cameroon is…
Island Pharmaceuticals
Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?
Island Pharmaceuticals Secures US Patent for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 12 per cent this week after announcing it secured a US patent for galidesivir, its antiviral drug designed to fight some of the world's deadliest viruses. While a broad US patent protects galidesivir’s use in COVID-19 until July 2042, the company just secured…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here